MedTrace Logo

Meropenem and Ciprofloxacin Dosing in Septic Shock

NCT02240277 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2014-09-15

No results posted yet for this study

Summary

Patients with septic shock may have altered volume of distribution and metabolism of antibiotics which are crucial medications for treating infections. The aim of the study is to investigate the blood concentrations of Meropenem and Ciprofloxacin, two commonly used antibiotics, in patients with septic shock. The hypothesis is that standard dosing may produce insufficient levels of antibiotics in patients with septic shock.

Conditions

  • Septic Shock

Sponsors & Collaborators

  • The University of Queensland

    collaborator OTHER

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Fredrik Sjoevall, MD, PhD · Rigshospitalet, Denmark

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-12-31
Completion
2016-03-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02240277 on ClinicalTrials.gov